Mitomycin-C 2mg / 10mg powder for injection
PDF Leaflet Revision Date: 25 November 2011
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various malignant tumors.
Dosage (summary)
12-14 mg/mu00b2 once a month or 10 mg/mu00b2 every 6-9 weeks for combination therapy.
Special Populations
- Hepatic impairment
- Renal impairment
- Bone marrow suppression
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy; safety during lactation not established.
Key Drug Interactions
- Increased leukopenia with blood dyscrasia-causing medications
- Increased cardiotoxicity with doxorubicin
Contraindications
- Active infection
- Pregnancy
- Hypersensitivity to MITOMYCIN-C
Common side effects
- Leucopenia
- Thrombocytopenia
- Nausea
- Vomiting
- Hypersensitivity reactions
Counselling Points
- Avoid pregnancy during treatment
- Breastfeeding not recommended
- Report any signs of infection or bleeding
Serious warnings
- Serious adverse effects may occur; monitor blood counts
- Risk of acute leukaemia and MDS with other antineoplastics
Important Disclaimer
The Mitomycin-C 2mg / 10mg powder for injection professional information leaflet below is the property of Aspen Pharmacare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
